Quote this publication Share Print

TRIUMEQ (dolutegravir/abacavir/lamivudine), fixed-dose combination of antiretrovirals

VIROLOGY - New medicinal product
Opinions on drugs - Posted on Jul 10 2015

Reason for request


No clinical benefit demonstrated when compared with taking the different components separately.

  • TRIUMEQ has Marketing Authorisation in the treatment of Human Immunodeficiency Virus (HIV)-infected adults and adolescents from 12 years of age weighing at least 40 kg and non-carriers of the HLA-B*5701 allele. 
  • TRIUMEQ enables treatment simplification when prescription of the abacavir + lamivudine + dolutegravir triple therapy is considered in treatment-naive or pre-treated patients, in whom the virus does not possess the resistance mutation to integrase inhibitors and the two NRTIs: abacavir and lamivudine.

Clinical Benefit



Clinical Added Value

no clinical added value


Therapeutic use


Contact Us

Évaluation des médicaments